ToolGen shares surge as Britain gives world's first nod to gene-editing treatment
Published
Modified
ToolGen, a Korean gene therapy developer, is trading strong in the Kosdaq market on Friday, as the British authorities granted the world's first approval for gene-editing treatment.
ToolGen share is trading at 61,800 won ($47.68) as of 11:05 a.m., up 29.83 percent from the previous trading day.
ToolGen holds a patent on so-called genetic scissors, a gene-editing tool.
Britain on Thursday became the first country in the world to give the nod to Casgevy, a Crispr gene-editing tool developed by Vertex Pharmaceuticals and Crispr Therapeutics, to treat hereditary blood disorders.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
